MicroRNA Expression Differentiates Squamous Epithelium from Barrett’s Esophagus and Esophageal Cancer by Garman, Katherine S. et al.
MicroRNA Expression Differentiates Squamous Epithelium from
Barrett’s Esophagus and Esophageal Cancer
Katherine S. Garman1,2, Kouros Owzar1, Elizabeth R. Hauser1,2, Kristen Westfall1, Blair R.
Anderson1, Rhonda F. Souza3,4, Anna Mae Diehl1, Dawn Provenzale2,1, and Nicholas J.
Shaheen5
1Duke University, Durham, NC
2Durham VA Medical Center, Durham, NC
3VA North Texas Health Care System – Dallas, Dallas, TX
4University of Texas Southwestern Medical Center, Dallas, TX
5University North Carolina at Chapel Hill, Chapel Hill, NC
Abstract
Background—Current strategies fail to identify most patients with esophageal adenocarcinoma
(EAC) before the disease becomes advanced and incurable. Given the dismal prognosis associated
with EAC, improvements in detection of early-stage esophageal neoplasia are needed.
Aims—We sought to assess whether differential expression of microRNAs could discriminate
between squamous epithelium, Barrett’s esophagus (BE), and EAC.
Methods—We analyzed microRNA expression in a discovery cohort of human endoscopic
biopsy samples from 36 patients representing normal squamous esophagus (n=11), BE (n=14), and
high-grade dysplasia (HGD)/EAC (n=11). RNA was assessed using microarrays representing 847
human microRNAs followed by qRT-PCR verification of nine microRNAs. In a second cohort
(n=18), qRT-PCR validation of five miRNAs was performed. Expression of 59 microRNAs
associated with BE/EAC in the literature was assessed in our training cohort. Known esophageal
cell lines were used to compare miRNA expression to tissue miRNAs.
Results—After controlling for multiple comparisons, we found 34 miRNAs differentially
expressed between squamous esophagus and BE/EAC by microarray analysis. However, miRNA
expression did not reliably differentiate non-dysplastic BE from EAC. In the validation cohort, all
five microRNAs selected for qRT-PCR validation differentiated between squamous samples and
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BE/EAC. Microarray results supported 14 of the previously reported microRNAs associated with
BE/EAC in the literature. Cell lines did not generally reflect miRNA expression found in vivo.
Conclusions—These data indicate that miRNAs differ between squamous esophageal
epithelium and BE/EAC, but do not distinguish between BE and EAC. We suggest prospective
evaluation of miRNAs in patients at high risk for EAC.
Keywords
Barrett esophagus; esophageal neoplasms; microarray analysis; microRNAs
Introduction
Risk stratification in esophageal neoplasia is inadequate. More than 90% of patients with
esophageal cancer are never diagnosed with a pre-malignant condition[1,2]. Endoscopic
screening and surveillance for esophageal neoplasia are expensive and have never been
proven to benefit patients in a randomized control trial [3]. Rather than presenting at a stage
when intervention is feasible, most patients with esophageal cancer present symptomatically
with advanced stage disease, by which time cure is unlikely. Improving the current 17%
five-year survival [4] associated with esophageal cancer will require a better strategy for
early identification and intervention.
The current clinical approach to Barrett’s esophagus (BE) and esophageal adenocarcinoma
(EAC) in the U.S. focuses on BE as the major risk factor for EAC. As suggested by
American Gastroenterological Association (AGA) guidelines, patients with risk factors for
EAC are screened for BE, and if BE is identified, they are entered into a program of
surveillance endoscopy [3]. Patients eligible for screening are currently identified by the
following factors: age 50 years or older, male sex, white race, chronic gastroesophageal
reflux disease (GERD), hiatal hernia, increased body mass index, increased intra-abdominal
body fat [3]. However, these risk factors identify a large proportion of the population, and
will identify relatively few cancers. Men who are over 60 with GERD have a risk of BE of
only 9.3% [5]. Also, the strategy of targeted screening for BE was based upon a suspected
progression rate from BE to EAC of 0.5%/year [6]. However, recent data suggest that the
rate of progression is markedly less, perhaps as low as 0.12%/year [2]. This rate of
progression is similar to the complication rate traditionally associated with upper endoscopy
[7]. Ideally, endoscopy could be reserved for patients who would benefit most from
screening, while minimizing harm in the large number of patients who have some risk
factors for EAC, but will never actually develop the disease.
MicroRNAs (miRNAs) are small non-coding RNA that modify gene expression within cells
[8]. Increasingly, miRNAs are being considered as potential biomarkers because they are
relatively stable molecules, less prone to degradation than larger RNA molecules. In
addition, miRNAs have been associated with unique patterns of expressions in cancers [9]
and identified with several different cancer types as both oncogenes and tumor suppressors
[10] [9,11] [12] [13]. We hypothesized that differential expression of miRNAs may be
associated with different phases of esophageal neoplasia from squamous mucosa to BE to
EAC.
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To evaluate miRNA expression in BE, total RNA was extracted from 36 endoscopically-
obtained unique biopsy samples from patients undergoing upper endoscopy for an indication
of either clinically-diagnosed GERD or histologically verified BE. While GERD and/or
known BE were the clinical indications for endoscopy, patients with erosive esophagitis
were excluded from this discovery miRNA analysis to minimize introduction of injury-
associated miRNA signal. Patients had been enrolled in the University of North Carolina
(UNC) at Chapel Hill esophageal tissue repository, a well-annotated repository that contains
samples of squamous esophagus, BE and EAC from adults presenting for upper endoscopy.
Each sample had a corresponding pathologic specimen from adjacent tissue interpreted by
an expert GI histopathologist. All patients provided informed consent, and the research was
approved by Institutional Review Boards at UNC and Duke University.
Samples consisted of three separate phenotypes: squamous esophagus (n=11), BE with no
dysplasia or low-grade dysplasia (n=14), and BE with high-grade dysplasia/superficial EAC
(n=11).
Clinical data were prospectively collected by a study coordinator using the medical record
and questionnaires completed at the time of endoscopy. Body mass index was calculated
from measurements obtained in duplicate. Smoking status was dichotomized as an ever/
never variable. Prior history of other non-esophageal cancers was elicited. Previous and
current endoscopic findings including diagnosis of erosive esophagitis and BE were
determined from patient report, the medical record and pathologic reports. BE was defined
as any length of endoscopically visible columnar mucosa in the tubular esophagus, with
biopsies that demonstrated intestinal metaplasia [14]. Unmatched samples representing
different tissue phenotypes were selected from the biorepository for genomic analysis.
RNA extraction
RNA extraction from frozen de-identified samples was performed using mirVana kits
(Ambion, Santa Clara, CA). Quality of the RNA was assessed based upon the RNA-
integrity number (RIN score) [15].
Inclusion/Exclusion
Acceptable samples were defined as those with a RIN score greater than six. Due to reported
changes in systemic (rather than tissue specific) changes in miRNA expression in cancer,
patients who carried a known prior diagnosis of a non-esophageal cancer were excluded
from this analysis. In addition, while all patients had a diagnosis of GERD or BE as the
indication for endoscopy, patients with erosive esophagitis at the time of endoscopy were
excluded.
miRNA Microarray
After quantification of total RNA, the RNA from each sample was labeled with a
biotinilated signal molecule using FlashTag Biotin HSR RNA labeling. Biotin-labeled
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samples and hybridization mastermix were incubated and injected into arrays. Then arrays
were washed and scanned using standard Affymetrix (Santa Clara, CA) protocol. Affymetrix
GeneChip miRNA Arrays representing 847 human miRNA probe sets were used to
characterize miRNA expression from each sample. Careful attention was paid to the six
essential elements of Minimum Information about a Microarray Experiment (MIAME 2.0)
standards in experimental design and data integrity assurance. Details of analysis can be
found in the statistical section at the end of this methods section. Briefly, the R statistical
environment [R] version 2.15.1 [16] was used for all analysis. Code was written to link
clinical annotation to cel files with the original file names and the MD5 Message-Digest
algorithm was used to assign a digital fingerprint to the clinical data and cel files. As
described later, the Robust Multichip Average (RMA) algorithm from the Bioconductor [17]
extension package affy (version 1.34.0) was used to pre-process the CEL files for
background correction, normalization, and calculation of expression values [18]. We
compared pre-processing using RMA to pre-processing using the miRNA QC tool available
from Affymetrix and found comparable results.
Verification of microarray results with qRT-PCR
Quantitative real-time polymerase chain reaction (qRT-PCR) for miRNAs was performed on
the same samples used for the microarray-based approach. The primary goal of qRT-
verification was to determine if the microarray and qRT-PCR assays would indicate similar
patterns of miRNA expression for a subset of probes represented on the microarrays
(selection process described in the analysis section). Because qRT-PCR results may be more
sensitive and specific than microarrays for miRNAs, it has been suggested that other
methods, such as qRT-PCR be used to verify microarray results [19]. In this study, given
limitations of availability of qRT-PCR reagents as well as a limiting quantity of original
RNA, only a subset of nine miRNAs from the initial microarray analysis was selected for
verification by qRT-PCR, and all results are reported. TaqMan miRNA primers and reagents
from Ambion (Life Technologies, Carlsbad, CA) were used. Additional details are listed in
supplemental materials and primers are listed in Supplemental Table 1. A threshold cycle
(CT) value was determined for each sample for analysis of qRT-PCR results. RNU48 was
selected as the control probe in all qRT-PCR analyses after comparing its performance to
RNU6 (by qRT-PCR) and finding less variability in expression for RNU48. One squamous
sample was excluded from qRT-PCR verification analysis due to a technical problem; this
resulted in 35 samples total for the PCR analysis portion of the study.
Validation set
A separate validation set was established to assess patterns of expression of miRNAs found
to be differentially expressed by microarray and qRT-PCR analysis in the discovery set.
Eighteen additional samples from UNC and the Duke Gastrointestinal Tissue Repository
were selected for creation of the validation cohort. Phenotypes included: squamous
epithelium from patients with reflux without BE (n=7), squamous epithelium from patients
with BE (n=4), Barrett’s biopsies (n=4), and EAC (n=3). Samples were removed from this
repository under an IRB protocol for miRNA expression studies. RNA extraction was
performed as described above, and quality of RNA was assessed with RIN scores.
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Analysis/Data Integrity—The microarray CEL files were pre-processed using the Robust
Multichip Average (RMA) approach [20]. There were 7815 features assessed for each
sample based upon the entire array. All 36 samples from the initial dataset were included in
the pre-processing. Further analysis of microarray data was limited to human probes as
characterized by “hsa” probe set ids; this limited the set of miRNA features to 847 human
probe sets.
In the discovery phase, we evaluated 847 probe sets from the miRNA microarray and
generated a list of the 34 miRNAs that demonstrated directional differences in expression
across the three ordered phenotypes: squamous, BE and EAC. Given the risk of multiple
comparisons and false-discovery associated with microarray experiments, a family-wise
error rate was used to adjust p-values and in the discovery phase. Microarray expression
values were used to calculate fold change between squamous and BE phenotypes and also
squamous and EAC. The goal was to identify miRNAs that demonstrated a step-wise
increase or decrease in expression from squamous to BE to HGD/EAC for further
validation.
Then, in the next step of the discovery phase, the top 34 miRNAs identified using
microarray methods in the discovery set were narrowed to a list of nine miRNAs for reasons
of statistical power (avoiding multiple comparisons) and experimental feasibility. The
following selection criteria were used to narrow the list. First, miRNAs that represented a
complementary strand (as indicated by a “star”) were excluded from further analysis based
upon the concern that complementary strands could be unstable and degraded (8 of 34) [21].
A bioinformatics approach was taken as per the National Center for Biotechnology and
Informatics (NCBI) and miRBase databases (www. http://www.mirbase.org/_) [22] to
determine the location of the miRNAs on the genome, to associate clusters of miRNAs, and
to identify related scientific citations. When two miRNAs from the same cluster were
available for analysis, one miRNA with strong expression in the microarray data was
selected for qRT-PCR verification. Some of the final selection of nine miRNAs for
verification was based upon reported association of miRNAs with cancers in the literature,
and this was the most subjective part of the selection process. Thus, we present not an
exhaustive assessment of all of the “top hits” identified through microarray analysis, but a
targeted assessment of nine miRNAs. Finally, a miRNA was excluded that previous
experience demonstrated would be difficult to verify with qRT-PCR (miR-30a).
The evaluation of nine miRNAs by qRT-PCR in 35 of the original RNA samples that had
been used for microarray analysis were then used to select a set of miRNAs for validation in
a separate dataset. The miRNAs selected for phenotypic validation in the separate dataset
were chosen based upon demonstration of concordant direction of expression between
microarray and qRT-PCR in discovery phase, strength of expression, and relatedness of
miRNAs (27a and 27b).
qRT-PCR Analysis
In TaqMan qRT-PCR analysis, a threshold representing a level of fluorescence signal
detection is determined. The threshold cycle (CT) values represent the PCR cycle number
when reporter fluorescence became greater than the determined threshold. Higher CT values
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indicate that it took more cycles to detect the particular miRNA of interest, meaning that
there is less of the miRNA of interest present in that sample. CT values in these experiments
were generated using a manually-determined threshold of 0.4 after visual inspection of the
amplification curves (to ensure parallel areas of the amplification curve). Average CT values
were determined for each sample based upon a combination of all replicates for that sample
and miRNA probe. Delta CT values were defined as the difference between probe and
control and were determined based upon the difference between the RNU48 control probe
average CT and the average CT of the probe of interest. Simply put, the average delta CT
quantitatively indicates the difference in the number of PCR cycles when the probes were
detected. The log (base 2) ratio of Delta CT of the probe and control was used to quantify
relative expression.
As was performed in the microarray analysis, miRNA probes were tested across the three
phenotypes. Concordance [23] was evaluated to quantify the association between expression
values for the microarray and qRT-PCR data for each sample.
Based upon discovery cohort results, which indicated more pronounced differences between
squamous and BE, and generally similar expression between BE and HGD/EAC, we did not
expect that this set of miRNAs would be able to determine a consistent difference between
BE and EAC samples in the validation cohort. Thus, the qRT-PCR validation analysis was
designed to evaluate expression between squamous samples (n=11) and a combined group
of BE and EAC samples (n=7).
Literature Validation
To test the utility of miRNAs previously reported to be associated with BE and EAC, an
additional analysis was performed using a list of candidate miRNAs gathered from a
systematic review of the literature. MEDLINE was searched and original reports assessing
miRNA expression in the BE adenocarcinoma sequence were obtained using combined
search terms of “miRNA or microRNAs” and “Barrett’s esophagus or esophageal
neoplasia,” yielding a list of 94 reports (search performed in September 2012). Of these, six
papers [24–30] were primary reports of overall miRNA expression including either BE or
EAC and provided sufficient detail about experiments and miRNA expression results to
allow generation of a list of differentially expressed miRNAs. Expression of each miRNA
was assessed using a non-parametric rank test.
Cell Line Validation
Finally, to compare miRNA expression from the in vivo experiments to those obtained from
culture, four cell lines that are frequently used to study BE and EAC were grown in culture.
Two squamous cell lines were included: NES-G2T (from patient without BE) and NES-B3T
(from a patient with BE)[31,32]. A Barrett’s cell line, BAR-T, was also included [32–34].
These telomerase-immortalized cell lines (provided courtesy of Rhonda Souza, MD), have
been described extensively in the Barrett’s literature. The OE-33 cell line (Sigma-Aldrich, St
Louis, MO) is a cell line derived from a BE-related EAC was the fourth cell-type assessed.
Cells were grown under standard conditions: OE33 cells were grown in RPMI 1640 with
2mM glutamine (Sigma-Aldrich, St Louis, MO) and 10% fetal bovine serum while the
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squamous and Barrett’s cell lines were grown per protocols developed by the Souza
lab, [32,33] Cells were grown to 80% confluence, and then RNA was extracted from cells
using mirVana kits. RNA quality was assessed, and only high-quality RNA was used for
microarray experiments (RIN 10). Three biologic replicates were used to generate biological
replicates for each of the different cell lines.
As described for the human samples in the training cohort, miRNA expression was assessed
for the four cell lines using Affymetrix miRNA arrays. The set of miRNA probes that
demonstrated differential expression in our human biopsy samples was specifically
evaluated in the cell lines to determine if cells in culture reflected patterns of expression in
human tissue.
The Flow Diagram in Figure 1 provides a schematic of the analysis performed from
discovery set through validation and indicates how the literature review and cell line
analysis are related to the discovery cohort.
Statistical Considerations
All statistical analyses were carried out using the R statistical environment [R] version
2.15.1 [16]. The implementation of the Robust Multichip Average (RMA) algorithm from
the Bioconductor [17] extension package affy (version 1.34.0) was used to pre-process the
CEL files[18]. In the discovery cohort, the Jonckheere-Terpstra test [35] [36] , a non-
parametric rank test, was used to generate the list of 34 miRNAs from the microarray
analysis, to analyze qRT-PCR results in the discovery cohort, and to analyze the microarray
data for literature validation and analysis of cell line results. The implementation of the
Jonckheere-Terpstra test from the clinfun extension package version 1.0.1 [37] was used in
this analysis. The Kendall Tau [23] measure of concordance was used to assess concordance
between microarray expression, and qRT-PCR cycle number. Validation was defined a
priori via Wilcoxon rank sum test of the validation cohort; i.e. the corresponding one-sided
family-wise error rate (FWER) (to limit type I error) was less than 0.05. The lattice (version
0.20-6) extension package was used for generating figures [38].
Results
Clinical features and demographics of the 36 patients in the initial cohort are represented in
Table 1. Patients with HGD/EAC tended to be older, and were more likely to be male than
patients from whom squamous or BE samples were obtained. Patients with HGD/EAC also
tended to have a higher average body mass index, and were more commonly smokers.
The initial microarray analysis on the training cohort yielded the top 34 miRNAs with
differential expression when assessing the three tissue types: squamous esophagus, BE, and
HGD/EAC. The complete list of top 34 miRNAs with raw and p-values adjusted for
multiple comparisons, as well as fold change, is reported in Supplemental Table 2. Also
shown in Supplemental Table 2, is the direction of expression in BE/EAC relative to
squamous epithelium is reported for the nine miRNAs selected for qRT-PCR verification.
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Results of microarray-based miRNA expression plotted against delta CT values from qRT-
PCR are shown in Figure 2 for nine miRNAs. This figure demonstrates two important
points. First, the direction of the miRNA expression is shown and the direction of expression
can be compared between microarray and qRT-PCR results. The predicted inverse
relationship between microarray expression and delta CT values exists for most of the
miRNAs. The one exception is miR-30b where there is no correlation between microarray
and qRT-PCR. Second, it is evident that a clearer distinction exists between squamous
samples (shown in blue) and the other two tissue types than between BE and EAC, where
there is significant overlap in the BE and HGD/EAC samples (green and red). As seen in
these plots, the differences in expression were largely driven by the differences between the
squamous and BE/EAC phenotypes.
On the basis of qRT-PCR analysis, seven of nine miRNAs assessed in the discovery cohort
were of sufficient quality to warrant phenotypic validation. Specific p-values for the qRT-
PCR analysis for all of the nine miRNAs are shown in Table 2. In addition, Table 2 reports
the concordance between expression values from microarray and the qRT-PCR miRNA. As
with the microarray results, differences in expression were much more pronounced between
squamous esophagus and BE/EAC than between BE and EAC.
In general, we found significant concordance between microarray results and qRT-PCR
results. In the verification of microarray results, if a true relationship existed between
microarray and qRT-PCR results, an inverse relationship between expression values and log
delta CT should be observed. Of the nine miRNAs assessed by microarray and qRT-PCR,
only miR-30b did not reveal the expected inverse relationship and neither miR-889 nor
miR-30b showed significant differential expression among the phenotype groups and were
consequently excluded from further phenotypic validation.
For miR-889 and miR-487b, miRNA expression in squamous samples was extremely low,
making the qRT-PCR results difficult to interpret as there was little separation between
samples, and cycle number was high, indicating very low levels (estimated at 0–2 copies) of
miRNA expression.
Validation
Five miRNAs: miR-21, miR-487b (both increased in BE and EAC) and miR-27b, miR-149,
miR-193b (decreased in BE and EAC), were selected for further validation in a separate
cohort. Discovery results guided the design of the validation study in terms of the phenotype
comparison and the selection of five miRNAs for validation in a separate cohort. Both
miR-30b and miR-889 were excluded based upon their performance in the qRT-PCR
verification. Given very low levels of expression on verification qRT-PCR, miR-92a (part of
the miR-106a cluster) was also excluded from the validation. Finally, miR-27b was selected
for validation and miR-27a was excluded as miR-27b demonstrated higher overall
expression.
In comparing the five miRNAs in esophageal squamous epithelium to samples with BE or
EAC, all five of the miRNAs were significantly differentially expressed between squamous
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and BE. Table 3 provides the p-values for the comparison of the five probes in squamous
versus BE/EAC samples.
All five miRNA probes performed in the hypothesized directions in the qRT-PCR
validation. Based upon a priori determination of significance, (p-value < 0.01 for each
individual probe in the one-sided Wilcoxon rank-sum test), miR-21, miR-27b, miR-149, and
miR-193b all validated in this cohort, with significant differences in expression between
squamous and BE/EAC samples.
Evaluation of miRNAs from the Literature
After performing a literature search for reports of miRNA expression in BE and/or EAC, we
identified a list of 59 miRNA probes. Then, we assessed the association of those miRNA
probes with BE and EAC in our discovery cohort. In the discovery dataset, 14 of the
miRNAs were expressed in a direction consistent with that reported in the literature; Table 4
lists these 14 miRNA probe sets, for which the marginal p value is less than 0.0008 (= 0.05 /
59), indicating significance. (Results for all 59 miRNAs are reported in Supplemental Table
3.) Again, the differences in expression were observed primarily in the squamous to
BE/EAC comparison.
When a miRNA had been reported in the BE and EAC literature multiple times, it was more
likely to be associated with BE/EAC in our training set. The 14 miRNAs from the literature
that met our significance threshold, controlling for multiple comparisons, were identified in
an average of 2.5 references compared to 1.1 references for the group that did not validate.
Cell Lines
Of the nine miRNAs included in our microarray analysis of miRNA expression in cell lines,
miR-92a expression by the cell lines most closely resembled the pattern of miRNA
expression found in our set of human samples with lower expression in BE/EAC, yet these
results differed miR-92 expression reported in the literature [29]. We found that the
squamous cells (NES-G2T and NES-B3T) expressed higher levels of miR-92a than the BE
cells with lower expression of miR-92a in the EAC-derived cell line OE33 cells (p-value
0.00592). Expression of miR21 also differed among cell lines: the adenocarcinoma cell line
(OE33) had the highest level of expression and slightly lower expression was found in NES-
B3T and BAR-T cells, however, the other squamous cell line (G2T) demonstrated miR-21
expression similar to the OE33 cells. Overall, the range of miRNA expression appeared to
be much more restricted in the cell lines than in the human esophageal tissue, resulting in far
smaller differences in microRNA expression across the spectrum of esophageal cell lines
than between benign versus neoplastic tissue samples from patients.
Discussion
We assessed whether differential expression of miRNAs could discriminate between
squamous epithelium, BE, and EAC. Based upon our analysis, we conclude that miR-21 and
miR-487b (increased in BE and EAC) as well as miR-27b, miR-193b, miR-149 (all
decreased in BE and EAC) demonstrate differential expression in squamous epithelium
compared to BE and EAC. However, we did not find miRNAs that consistently differed
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between BE and EAC. These findings highlight the overall similarity in miRNA expression
between BE and EAC [24,39] and suggest that miRNAs can be used to distinguish between
squamous esophagus and BE, but not between BE, BE with dysplasia, and EAC.
Several of the miRNAs reported here are novel: miR-193b has not been previously reported
as decreased in BE and EAC. Neither miR-889 nor miR-487b had previously been noted as
increased in BE or EAC. Our qRT-PCR results revealed high CT values for miR-889 and
miR-487b, indicating very low levels of expression in squamous epithelium compared to the
increased expression in BE and EAC, making these potentially useful biomarkers.
The approach to select for miRNAs that increase or decrease expression from squamous to
BE to EAC does not capture all biology (as some miRNAs may increase in the metaplasia
from squamous to BE, but decrease in the progression to cancer). Several of the miRNAs
identified as highly expressed in BE are linked to the intestinal phenotype, and are expressed
in the mouse small intestine [40]. Logically, this similarity between BE and intestinal
phenotype makes sense, and recently, investigators have begun to assess the role of specific
miRNAs (such as miR-145) in the development of BE [41]. Some of the miRNAs that
increase in BE then decrease in some EACs as the cancer phenotype develops. Because our
goal was to advance the field of biomarker development, we focused on miRNAs with the
step-wise increase across phenotypes, a reasonable strategy for possible biomarker
identification that has been recently described by other groups [39].
Previous studies have described miR-203 and miR-205 as highly expressed in squamous
epithelium compared to BE or EAC, while miR-21 and miR-194 have demonstrated
increased expression in BE, gastric epithelium, and EAC compared to squamous esophageal
epithelium [24],[28–30]. Most recently, Bansal and colleagues identified miRNAs that were
differentially expressed in patients with Barrett’s esophagus with and without dysplasia [26].
However, these attempts have not resulted in a consensus list of miRNAs to be used in
prospective studies to aid in risk-stratification. In an effort to derive such a list of likely
biomarker candidates, we provided an additional analysis of these reported miRNAs in our
own cohort, supporting some, but not all, of the previous findings.
We were able to reproduce results from the literature for 14 miRNAs previously reported as
associated with BE/EAC using our microarray dataset. In our analysis, miR143, miR145,
miR-21, miR-192, miR-194, miR-215 were all increased in BE and EAC while miR-203,
miR-205, miR-27b, miR-99c, miR-149, miR-210, miR-221, and miR-617 were all decreased
in BE/EAC. Six of these miRNAs were identified by our initial original microarray analysis.
However, these miRNAs did not reliably discern non-dysplasic BE from HGD/EAC.
As noted, none of the miRNAs tested reliably distinguished non-dysplastic BE from HGD/
EAC. This has implications for how such a biomarker might be used. Because endoscopists
do not generally have difficulty discerning between squamous and Barrett’s mucosa, assay
of these miRNAs in endoscopic biopsies may be of limited utility. On the other hand, a
biomarker that differentiates squamous from BE tissue might be of great use in the ongoing
development of non-endoscopic methods for BE screening in a targeted population at risk
for EAC based on clinical risk factors. An initial, relatively inexpensive, non-endoscopic test
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such as the recently described swallowed sponge[42] might act as a gateway to endoscopy
for those who are likely to have BE based upon a miRNA-based biomarker, resulting in cost
savings with little loss in diagnostic sensitivity.
There are several limitations to the work presented here. This is a cross-sectional study and
the temporal appearance of the biomarkers is difficult to ascertain from such a study. To
better understand the potential utility of miRNAs in risk stratification in BE, future studies
should include a prospective cohort study of high-risk patients. Assessment of miRNAs
from esophageal specimens, as well as miRNA expression from peripheral blood in these
patients when they underwent upper endoscopies over years would be ideal. Another
limitation is our reliance upon paired biopsies used to classify samples histologically. Using
histologic classification as a gold-standard is not ideal, although in cross-sectional studies,
there are no alternatives. It is well-known that pathologists experience considerable intra-
and inter-rater disagreement in their classification of BE [43]. For this reason, a separate
category of LGD was not included. Similarly, HGD and EAC were also grouped together in
our cohort, representing advanced neoplasia. In general, pathologists agree on the general
diagnosis of BE versus squamous tissue, and EAC versus BE. Cellularity of different tissue
samples (squamous, BE, EAC) may not be equal, and this could account for some of our
findings. We acknowledge that our validation sample-size was small, and as such, we
limited the number of miRNAs selected for validation to only five. It is also worth noting
that microarrays are limited as a miRNA detection technology by reliance upon uniform
hybridization conditions and as such, do not always correlate with qRT-PCR microRNA
results [19]. For the probes we assessed by qRT-PCR, correlation with microarray was good.
While verification of several miRNAs identified through microarray was performed, future
work could continue qRT-PCR verification of microarray findings. Finally, at the time that
this study was designed and initiated, RNA-Seq, which is now rapidly becoming the gold-
standard method for assessing RNA expression, was not readily available [44]. Even now,
small RNAs may be difficult when miRNAs with low copy number are of interest [19].
There are also several strengths to this study. Our study design included separate discovery
and validation cohorts. We approached the question of miRNA expression using an original
analysis as well as an assessment of the reproducibility of results from miRNA studies
published in the literature. The cell line experiments here add depth to this report,
contrasting miRNA expression in human cell lines with concurrent in vivo work. The results
of the in vitro experiments suggest a cautionary approach in the interpretation of cell culture
studies of miRNA in the development of EAC, as the cell culture studies do not reflect
findings found in vivo.
There are several potential explanations for differences between human tissue miRNA
expression and that found in cell culture. Changes in miRNA expression could be related to
the immortalization process, the cell culture media conditions, or a non-epithelial esophageal
cell type may be needed to express or support expression of miRNAs in culture.
In our study, miR-21 differentiated squamous from BE tissue. More than any other
microRNA, increased expression of miR-21 has been associated with many cancers [13]. In
a transgenic animal model, miR-21 has been clearly linked to carcinogenesis. In the animals
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with over-expression of miR-21 in lymph and brain tissues, lymphoid tumors developed that
then regressed after inactivation of miR-21. As for its gene targets, miR-21 targets the 3’-
UTR of programmed cell death 4 (PDCD4) and miR-21 is a negative regulator of PDCD4
[45]. Fassan et al showed that the basal layer of normal squamous epithelium and the non-
intestinal columnar metaplasia demonstrated PDCD4, but this target was lost in dysplasia
and EAC as predicted [46]. Thus, miR-21 is an especially interesting miRNA because of the
current data and given its putative function as a cancer-causing miRNA.
Our study suggests distinct miRNA expression in a comparison of squamous and BE/EAC
tissue, with notable similarities between miRNA expression in BE and EAC. In this cross-
sectional study, miRNAs did not distinguish between grades of dysplasia. While the current
study cannot support the use of miRNAs as biomarkers for BE dysplasia, moving forward,
these results may have the greatest clinical value in non-endoscopic screening for BE in
patients who are at risk for EAC. This might advance care by targeting endoscopy to
patients who are most likely to both have BE (based upon non-invasive miRNA
biomarkers). Even the population of patients who are at increased risk of EAC based upon
clinical risks such as male sex, white race, age, GERD history, family history or smoking
status still has a relatively low risk of developing EAC. A non-invasive screening test for BE
would help narrow the field of patients most likely to benefit from upper endoscopy.
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This flow diagram represents the steps in the analysis using the discovery cohort and a
separate validation cohort. Several steps we involved as the initial set of 847 miRNA probe
sets from the microarray was narrowed to a list of five miRNAs for validation.
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In this figure, the vertical axis represents expression by microarray analysis and the
horizontal access represents the delta CT values for each of the nine miRNA selected for
qRT-PCR verification of microarray results. This figure provides information on direction of
expression by tissue type for both the microarray and PCR platforms. Blue represents
squamous samples, green represent BE, while red represents EAC. miR-889, miR-487b,
miR-30b and miR-21 increased in BE compared to squamous. miR-27a, miR-92a, miR-27b,
miR-193b and miR-149 decreased in BE compared to squamous. The figure also
demonstrates concordance between microarray and qRT-PCR results (high concordance
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appears as a diagonal line). In general, the miRNA expression differentiated squamous
tissue from BE/EAC, but not BE from EAC.
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Table 1








Age – mean (sdv) 51.2 (11.2) 59.5 (13.1) 63.5 (7.9)
Men – n (%) 6 (55%) 8 (57%) 9 (82%)
Race (white) – n (%) 8 (72%) 14 (100%) 10 (91%)
BMI – mean (sdv) 27.3 (5.9) 27.0 (4.2) 31.2 (5.0)
Smoking – n (%) 6 (55%) 8 (57%) 10 (91%)
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Table 2
Significance test results of the discovery cohort for both microarray data and delta CT values for each qRT-
PCR probe. Concordance between microarray and qRT-PCR results is presented in the fourth column; a
negative tau is expected when there is a true relationship between microarray and qRT-PCR results given the






miR-149 2.82e-05 2.83e-04 −0.720 1.86e-10
miR-193b 4.65e-06 7.21e-05 −0.660 2.46e-08
miR-21 3.29e-05 6.95e-05 −0.431 3.83e-04
miR-27a 1.71e-07 2.86e-03 −0.452 1.89e-04
miR-27b 2.27e-06 7.19e-04 −0.563 4.04e-06
miR-30b 7.78e-06 7.87e-01 0.0538 6.86e-01
miR-487b 1.30e-06 6.56e-03 −0.343 5.47e-03
miR-889 1.18e-10 3.82e-01 −5.75e-02 6.71e-01
miR-92a 1.30e-06 4.87e-05 −6.01e-01 2.42e-07
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Table 3







miR-21 0.00022 increased Chromosome 17q23.1
miR-487b 0.0077 increased Chromosome 14q32.31
miR-27b 0.0023 decreased Chromosome 9q22.32
miR-149 0.00060 decreased Chromosome 2q37.3
miR-193b 0.00060 decreased Chromosome 16p13.12
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Table 4
Microarray Data for the miRNAs identified through Literature Review: In this table, we list all of the miRNA
probes for which the marginal p-value is less than 0.0008 (=0.05 / 59).
miRNA Direction of Expression Validation
p-value
hsa-miR-143_st Increased in BE/EAC [25,30] 0.00038
hsa-miR-145_st Increased in BE/EAC [25,30] 0.000323
hsa-miR-21_st Increased in BE/EAC [24,29,30] 4.1 × 10−05*
hsa-miR-192_st Increased in BE/EAC [24,26,28,29] 1.39 × 10−05
hsa-miR-194_st Increased in BE/EAC [24,28,30] 9.78 × 10−06
hsa-miR-215_st Increased in BE/EAC [28–30] 7.16 × 10−05
hsa-miR-203_st Decreased in BE/EAC [24,25,29,30] 7.54 × 10−05
hsa-miR-205_st Decreased in BE/EAC [24,25,29,30] 1.17 × 10−05
hsa-miR-27b_st Decreased in EAC [24,25] 1.22 × 10−05*
hsa-miR-99a_st Decreased in EAC [25,28] 3.53 × 10−05*
hsa-miR-149_st Decreased in EAC [25] 1.69 × 10−05*
hsa-miR-210_st Decreased in EAC [25] 0.000246
hsa-miR-221_st Decreased in EAC [25] 1.89 × 10−05
hsa-miR-617_st Decreased in EAC [25] 4.25 × 10−05*
An asterix identifies miRNAs included in our list of 30 miRNAs identified by microarray in the discovery cohort.
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